We serve Chemical Name:1,2,3,4-Tetrahydro-1,4-methanonaphthalene-2,3-dimethanol CAS:56306-51-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:1,2,3,4-Tetrahydro-1,4-methanonaphthalene-2,3-dimethanol
CAS.NO:56306-51-5
Synonyms:1,2,3,4-Tetrahydro-1,4-methanonaphthalene-2,3-dimethanol
Molecular Formula:C13H16O2
Molecular Weight:204.26500
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:369.4ºC at 760mmHg
Density:1.186g/cm3
Index of Refraction:1.59
PSA:40.46000
Exact Mass:204.11500
LogP:1.48810
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 1,2,3,4-Tetrahydro-1,4-methanonaphthalene-2,3-dimethanol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1,2,3,4-Tetrahydro-1,4-methanonaphthalene-2,3-dimethanol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1,2,3,4-Tetrahydro-1,4-methanonaphthalene-2,3-dimethanol Use and application,1,2,3,4-Tetrahydro-1,4-methanonaphthalene-2,3-dimethanol technical grade,usp/ep/jp grade.
Related News: In the US, however, ODAC in April voted to keep alive the accelerated approval for Tecentriq plus Abraxane (nab-paclitaxel) in mTNBC while additional confirmatory trials are ongoing. Methyl (S)-(+)-2-(2-methoxyphenyl)propanoate manufacturers Since it emerged as a shareholder of GSK in April, Elliott has reportedly been trying to gin up investor support to move Walmsley to the consumer health spinoff rather than to let her lead the new GSK after the separation. d(ACC) suppliers Since it emerged as a shareholder of GSK in April, Elliott has reportedly been trying to gin up investor support to move Walmsley to the consumer health spinoff rather than to let her lead the new GSK after the separation. 3-{[2-(6-fluoropyridin-2-yl)-imidazol-1-yl]methyl}-6-(3-methoxypropyl)-4-propylpyridazine vendor & factory Though the program obtained priority review from FDA back in November, analysts expressed skepticism in July 2020 after it failed to prove superior to the companies’ other drug Lumizyme in improving respiratory function in a Phase III trial.,Though the program obtained priority review from FDA back in November, analysts expressed skepticism in July 2020 after it failed to prove superior to the companies’ other drug Lumizyme in improving respiratory function in a Phase III trial.
